Gut-targeted cannabinoid treatment improves cognition in fragile X mice

Low-Res_tractament-experimental-millora-capacitat-cognitiva-microbiota-x-fragil-upf

A drug that blocks cannabinoid receptors outside the brain improved memory, synaptic function and gut abnormalities in mouse models of fragile X syndrome. The findings strengthen evidence that the microbiota–gut–brain axis may contribute to cognitive symptoms and could offer a new route for developing treatments with fewer central nervous system effects.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE